General Hospital Psychiatry
Volume 27, Issue 2 , Pages 140-144 , March 2005

Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study

Received 31 May 2004 ,Accepted 26 November 2004.

References 

  1. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs. 2002;16:219–228
  2. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J. Clin. Psychiatry. 2000;61:933–941
  3. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology. 2001;155:128–134
  4. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J. Clin. Psychiatry. 2001;62:12–18
  5. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: Comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology [in press].
  6. Shale JH, Shale CM, Mastin WD. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J. Clin. Psychiatry. 2003;64:500–505
  7. Swift RH, Harrigan EP, Cappelleri JC. Validation of the behavioral activity rating scale (BARS™): a novel measure of activity in agitated patients. J. Psychiatr. Res. 2002;36:87–95
  8. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry. 2001;158:1149–1151
  9. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry. 2002;59:441–448
  10. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. (England). 2003;6:325–337
  11. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 2002;63:763–771

PII: S0163-8343(04)00140-9

doi: 10.1016/j.genhosppsych.2004.11.004

General Hospital Psychiatry
Volume 27, Issue 2 , Pages 140-144 , March 2005

Article Tools

* Image Usage & Resolution